<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">JBPC</journal-id><journal-title-group><journal-title>Journal of Biophysical Chemistry</journal-title></journal-title-group><issn pub-type="epub">2153-036X</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/jbpc.2012.32019</article-id><article-id pub-id-type="publisher-id">JBPC-19439</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Chemistry&amp;Materials Science</subject></subj-group></article-categories><title-group><article-title>
 
 
  Role of endothelium on the abnormal Angiotensin-mediated vascular functions in epileptic rats
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>arolina</surname><given-names>Restini</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Rosana</surname><given-names>Reis</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Claudio</surname><given-names>Costa-Neto</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Norberto</surname><given-names>Garcia-Cairasco</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>José</surname><given-names>Cortes-de-Oliveira</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Lusiane</surname><given-names>Bendhack</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>Faculdade de Ciências Farmacêuticas de Ribeir?o Preto-USP, Ribeir?o Preto, Brasil</addr-line></aff><aff id="aff2"><addr-line>Faculdade de Medicina de Ribeir?o Preto-USP, Ribeir?o Preto, Brasil</addr-line></aff><aff id="aff1"><addr-line>Universidade de Ribeira?o Preto—UNAERP. Curso de Medicina, Ribeirāo Preto, Brasil</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>carolbaraldi@hotmail.com(AR)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>29</day><month>05</month><year>2012</year></pub-date><volume>03</volume><issue>02</issue><fpage>174</fpage><lpage>182</lpage><history><date date-type="received"><day>28</day>	<month>January</month>	<year>2012</year></date><date date-type="rev-recd"><day>20</day>	<month>February</month>	<year>2012</year>	</date><date date-type="accepted"><day>14</day>	<month>March</month>	<year>2012</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Epidemiological studies have found that the risk for cardiovascular disease is increased in patients with epilepsy. The Renin Angiontensin System (RAS), an important player in vascular tone control, is also involved in many neurological disorders, including seizures and epilepsy. Although it has been reported that Angiotensin II (Ang II) release and Angiotensin receptors expression are altered in many cerebral areas in patients/animal models with neurological disorders, there are no data on the vascular function. We evaluated Ang I and Ang II-mediated vascular responses and to correlate their contractile responses to the pres- ence of endothelium and the protein levels of components of the RAS (AT
  <sub>1</sub>, AT
  <sub>2</sub>, Mas and ACE) in aorta isolated from genetically epileptic rats (WAR strain). The major finding was that the vascular contractile response induced by Ang I and Ang II is endothelium-dependent. Ang II induced contractions in aortas from Wistar rats either with intact endothelium (E+) (1.16 &#177; 0.04 g, n = 6) and endothelium-denuded (E-) (1.24 &#177; 0.04 g, n = 6). Maximum contractile response (ME) induced by Ang I was lower in Wistar E+ (0.45 &#177; 0.03 g, n = 6) compared with Wistar E- (1.13 &#177; 0.08 g, n = 6). Ang I and Ang II failed to induce contraction in WAR E+, whereas the ME induced by Ang I in WAR E- was lower (0.52 &#177; 0.04 g, n = 11) than in the Wistar. ME induced by Ang II in aortas from WAR was also lower (0.40 &#177; 0.03 g, n = 11) compared with Wistar. AT
  <sub>1</sub> receptor expression in both E+ WAR and Wistar was lower than in both E- WAR and Wistar. AT
  <sub>2</sub> and Mas receptor expression was higher in Wistar E- and E+ as compared to WAR E- and E+. ACE expression was higher in both E+ WAR and Wistar, but it was lower in both E- WAR and Wistar. Endothelium impairs the contractile response induced by Angiotensin in WAR, suggesting that endothelial relaxing factors play important role on the aorta contraction.
 
</p></abstract><kwd-group><kwd>Endothelium; Aorta Myogenic Tone; Angiotensin; Angiotensin II Receptor; Epilepsy</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. INTRODUCTION</title><p>Epidemiological studies have found that the risk for cardiovascular disease is increased in persons with epilepsy and it is related to premature death [1-6]. The Renin-Angiotensin System (RAS) is a player in many neurological disorders, including seizures and epilepsy. It has been pointed out that the RAS is a mediator in neurological problems such as the seizures observed in epilepsy and cardiovascular diseases [<xref ref-type="bibr" rid="scirp.19439-ref7">7</xref>].</p><p>Considering epilepsy as a neurodegenerative disorder, important studies of Tchekalarova and Georgiev [<xref ref-type="bibr" rid="scirp.19439-ref7">7</xref>] have demonstrated the brain involvement of the RAS in seizure genesis and/or control by activation of the AT<sub>1</sub> receptor, thereby facilitating the discharge firing. Arga&#241;araz et al. [<xref ref-type="bibr" rid="scirp.19439-ref8">8</xref>] have reported increased AT<sub>1</sub> receptor expression in the cortex and in the hippocampus of patients with temporal lobe epilepsy, while AT<sub>2</sub> receptor expression was elevated only in the hippocampus of these patients. According to these authors, changes in Angiotensin II (Ang II) release may occur via mechanisms that remain unknown. Ang II would have proor anti-epileptogenic function depending on its receptor activation. Their findings suggest that the up-regulation of the AT<sub>1</sub> receptor is related to increased tissue excitability in the hippocampus and cortical areas.</p><p>Regarding to the peripheral actions of RAS it is important to consider that the RAS plays a relevant role in blood pressure and body fluid homeostasis regulation [9-12]. Angiotensin I (Ang I) is the main substrate for the Angiotensin Converting Enzyme (ACE), yielding the vasoconstrictor Ang II, the main RAS effector [<xref ref-type="bibr" rid="scirp.19439-ref13">13</xref>]. Ang I may also be hydrolyzed by prolyl-endopeptidase and carboxy-peptidases, to yield the vasodilator Angiotensin-1-7 (Ang 1-7) [<xref ref-type="bibr" rid="scirp.19439-ref14">14</xref>]. However, Ang II is the major substrate for (Ang 1-7) synthesis [<xref ref-type="bibr" rid="scirp.19439-ref15">15</xref>]. Besides the AT<sub>1</sub> and AT<sub>2</sub> receptors, the GPCR Mas has been identified as an endogenous receptor for the Angiotensin-(1-7) [16-18].</p><p>Ang II exerts its effect through activation of type 1 (AT<sub>1</sub>) and type 2 (AT<sub>2</sub>) receptors belonging to the family of G-protein coupled receptors (GPCRs). Both types of receptor trigger distinct and sometimes opposing signal transduction pathways<sup> </sup>[19,20]. The most prevalent physiological and pathological effects of Ang II, such as vascular smooth muscle cell contraction, are mediated by the AT<sub>1</sub> receptor. On the other hand, AT<sub>2</sub> receptors are generally assumed to counteract these actions. Activation of AT<sub>2</sub> receptors leads to several biological processes, such as vascular relaxation [21-24].</p><p>It is well known that the RAS and the nitric oxide (NO) system play a crucial part in the regulation of cardiovascular physiology and pathology [<xref ref-type="bibr" rid="scirp.19439-ref25">25</xref>]. According to Yan et al. [<xref ref-type="bibr" rid="scirp.19439-ref25">25</xref>] there is a functional relationship between Ang Iotensin II and NO. Nitric Oxide is the main relaxing endothelial factor involved on the aorta relaxation [26,27]. Works using cultured neurons have demonstrated that NO is specifically involved in mediating Ang II actions [28,29]. Ang II is also considered a neurotransmitter/ neuromodulator, because it is responsible for the activetion of AT<sub>1</sub> and AT<sub>2</sub> receptors present in several brain regions [30-32]. Although the importance of animal models for the investigation of epilepsy and related disorders is recognized, few studies have been devoted to the relationship between epilepsy and peripheral vascular dysfunctions focusing on endothelium, whose co-morbidities are involved in this neurological disorder.</p><p>Growing evidence has indicated the participation of RAS in some neurodegenerative disorders such as Alzheimer’s [33,34], Parkinson’s [<xref ref-type="bibr" rid="scirp.19439-ref35">35</xref>] and Huntington’s [<xref ref-type="bibr" rid="scirp.19439-ref36">36</xref>] diseases. Genetic models of epilepsy have played a crucial role in the elucidation of the pharmacological, electrophysiological, and neuroethological aspects of generalized seizures [37,38]. Of our particular interest is the genetically audiogenic susceptible rodents, the so-called Wistar audiogenic rats (WAR), which present severe co-morbidities [<xref ref-type="bibr" rid="scirp.19439-ref39">39</xref>]. The WAR strain was first obtained by Garcia-Cairasco [<xref ref-type="bibr" rid="scirp.19439-ref40">40</xref>] and has been proven useful for characterization of behavioral sequences in acute audiogenic seizures [41-44], audiogenic kindling studies [45-48], screening of new anticonvulsant agents [<xref ref-type="bibr" rid="scirp.19439-ref49">49</xref>] and research on the neurochemistry of audiogenic seizures [50,51]. Multiple inductions of audiogenic seizures in the WAR strain are a model of temporal lobe epilepsy, due to the recruitment of limbic areas such as hippocampus and amygdale [<xref ref-type="bibr" rid="scirp.19439-ref52">52</xref>].</p><p>Although it has been reported that Ang II release and Angiotensin receptors function/expression are altered in many cerebral areas in patients/animal models with neurological disorders, there are no data on the vascular function to Angiotensin peptides of genetically audiogenic susceptible rodents such as the Wistar audiogenic rats (WAR), a model of temporal lobe epilepsy and therefore it has been considered to evaluate the vascular function (vascular reactivity to Angiotensin peptides in WARs.</p><p>Therefore, it was hypothesized that the contractile response to Ang I and Ang II is altered in the aorta isolated from rats of the WAR strain. Because of this, our work was designed to evaluate the importance of the endothelium on Angiotensin-mediated vascular responses and to investigate the mechanisms involved in the vascular function of Wistar audiogenic rats.</p></sec><sec id="s2"><title>2. METHODS</title><sec id="s2_1"><title>2.1. Animals</title><p>Male WAR and Wistar rats (Control) aged 80 days were employed. WAR belonged to the inbred strain of the Physiology Department of Faculdade de Medicina de Ribeir&#227;o Preto, University of S&#227;o Paulo, Brazil [<xref ref-type="bibr" rid="scirp.19439-ref23">23</xref>]. Water and food were available ad libitum and room temperature was controlled at 23˚C, in a 12 h light/dark circle. All the experiments were performed in accordance with the recommendations of the Brazilian Society for Neuroscience and Behavior for animal experimentation and were approved by the Ethics Commitee on Animal Research of the School of Medicine of Ribeir&#227;o Preto, University of S&#227;o Paulo, Brazil (CETEA, protocol n. 124/2005). All efforts were made in order to avoid any unnecessary animal suffering and to reduce the number of animals employed in the experiments. In order to characterize the model, in its genetic component, it was employed only na&#239;ve animals, it was not our aim to obtain epileptic behavior after sound stimulation, i.e., and there were no audiogenic stimuli to induce seizures in the WAR.</p></sec><sec id="s2_2"><title>2.2. Systolic Blood Pressure Measurement</title><p>Systolic Blood Pressure (SBP) was measured in conscious rats by an indirect tail-cuff method (MLT125R Pulse Transducer/Pressure Cuff coupled to the PowerLab 4/S analogue-to-digital converter, AD Instruments Pty Ltd).</p></sec><sec id="s2_3"><title>2.3. Vascular Reactivity Studies</title><p>Rats were killed by decapitation. The thoracic aorta was quickly removed, dissected out, and cut into 4 mm long rings. In some experimental protocols, the effect of the drugs in endothelium-denuded arteries was studiedin order to avoid interference from endothelium factors. To this end, the endothelium was mechanically removed by gently rolling the lumen of the vessel on a thin wire. The aortic rings were placed between two stainless-steel stirrups and connected to an isometric force transducer (Letica Scientific Instruments; Barcelona-Spain), to measure the tension in the vessels. The rings were placed in a 10 mL organ chamber containing Krebs solution with the following composition (mmol/L): NaCl 130, KCl 4.7, KH<sub>2</sub>PO<sub>4</sub> 1.2, MgSO<sub>4</sub> 1.2, NaHCO<sub>3</sub> 14.9, glucose 5.5, and CaCl<sub>2</sub> 1.6. The solution was maintained at pH 7.4 and was gassed with 95% O<sub>2</sub> and 5% CO<sub>2</sub> at 37˚C. The rings were stretched to a basal tension of 1.5 g before allowing them to equilibrate for 60 min in the bath fluid, which was changed every 15 min. Endothelial integrity was qualitatively assessed by the degree of relaxation caused by acetylcholine (1 μmol/L) in the presence of the contractile tone induced by norepinephrine (0.1 μmol/L). For the studies, which required endothelium-intact aortas (E+), the rings that presented more than 90% of relaxation when stimulated with acetylcholine were considered. The arteries were considered endothelium-denuded (E–) if there was not any degree of relaxation upon stimulation with acetylcholine. Then, cumulative effect-concentration curves were constructed for Ang I and Ang II (10 ρmol/L - 10 μmol/L).</p></sec><sec id="s2_4"><title>2.4. AT<sub>1</sub>, AT<sub>2</sub>, Mas and ACE Expression</title><p>This experimental procedure was designed to quantify the protein expression of AT<sub>1</sub> and AT<sub>2</sub> receptors as well as ACE, as a function of the expression of β-actin in control and WAR. Briefly, the aortic rings were isolated from WAR and control. Protein extraction from the tissues with or without endothelium was performed by maceration using lysis buffer consisting of Tris-HCl 10 mmol/L, pH 7.5, NaCl 150 mmol/L, EDTA 1 mmol/L, EGTA 1 mmol/L, SDS 0.1%, Nonidet P-40 1% and the following protease inhibitors: PMSF 2 mmol/L, SBTI 100 mg/mL, leupeptin 10 mg/mL, aprotinin100 mg/mL, benzamidin 10 mmol/L, and sodium orthovanadate 2 mmol/L. After 30 min of homogenization at 4˚C, the lysate was centrifuged for 15 min at 4˚C and 13,000 rpm, and total protein was measured using a commercial kit (Anresco). Then, 5 - 20 mg of total protein was separated by SDS-PAGE (12% for the Ang II receptors and 10% for ACE) and transferred to a nitrocellulose membrane, and Western Blotting was performed for AT<sub>1</sub>, AT<sub>2</sub>, and Mas receptors and for ACE. The membrane blocked with 3% BSA (in TTBS). The primary antibodies were diluted in TTBS + 3% BSA, 1:1000. The secondary antibodies were diluted in 1:3000 (anti-rabbit, purchased from Santa Cruz). The bands were developed by using an enhanced chemiluminescence kit. The membranes were deblotted, and Western Blotting for β-actin was developed.</p></sec><sec id="s2_5"><title>2.5. Drugs</title><p>Acetylcholine, norepinephrine, Angiotensin I, and angiotensin II were obtained from Sigma Chem. Co. (St Louis, MO-USA). Solutions of the drugs were prepared in deionized water. All the antibodies employed in the Western Blotting analyses were purchased from Santa Cruz Biotechnology, Inc.</p></sec><sec id="s2_6"><title>2.6. Data Analysis</title><p>Data are expressed as mean &#177; SEM. In each set of experiments, n indicates the number of studied rats.</p><p>The Western Blotting data were expressed by the intensity of the bands, which were measured by densitometry. Densitometric values obtained with the aid of the Image J program (http://rsb.info.nhi.gov/ij/) were used to calculate the rate of AT<sub>1</sub> and AT2 receptors and ACE as a function of the β-actin expression, and the corresponding results were plotted using the Graph-Pad software (GraphPad, San Diego, CA).</p><p>The data were statistically analyzed by Student’s t-test or by ANOVA (one-way), followed by the NewmanKeuls post-test. Tests were employed according to the data. A value of p &lt; 0.05 was considered significantly different.</p></sec></sec><sec id="s3"><title>3. RESULTS</title><p>The systolic pressure measured by the tail-cuff method was higher in WAR (120 &#177; 2 mmHg, n = 15, p &lt; 0.05) as compared to the Wistar (90 &#177; 2.0 mmHg, n = 16) (<xref ref-type="fig" rid="fig">Figure </xref>not shown).</p><p>In order to study the vascular reactivity to the agonists of the renin-Angiotensin system (RAS), it was constructed concentration-effect curves for Ang I and Ang II. The influence of endothelium on the contractile responses induced by Ang I and Ang II in aortic rings isolated from WAR and Wistar was examined by using intact-endothelium (E+, Figures 1(a) and 1(b)) and denuded (E–, Figures 2(a) and (b)) arteries.</p><p>As shown in <xref ref-type="fig" rid="fig">Figure </xref>1(a), in Wistar E+ both Ang I and Ang II induced contractile response with the maximum effect (ME) of 0.45 &#177; 0.03 g (n = 6) and 1.16 &#177; 0.04 g (n = 6), respectively. This response was significantly higher for Ang II than Ang I (p &lt; 0.01). On the other hand, Ang I (ME: 0.10 &#177; 0.008 g, n = 10) and Ang II-induced contractile responses (ME: 0.09 &#177; 0.008 g, n = 7) were almost abolished in aortic rings from WAR E+ (<xref ref-type="fig" rid="fig">Figure </xref>1(b)).</p><p>In order to investigate if this response was abolished only to RAS agonists, the contractile response to phenylephrine as an adrenergic agonist was also evaluated in intact endothelium aortic rings. Differently of the Ang I and Ang II-induced responses, PHE was able to trigger contractile response in both Wistar (ME: 2.0 &#177; 0.06 g, n = 6) (<xref ref-type="fig" rid="fig">Figure </xref>1(a)) and WAR (ME: 1.50 &#177; 0.02 g, n = 9) (<xref ref-type="fig" rid="fig">Figure </xref>1(b)).</p><p>As depicted in <xref ref-type="fig" rid="fig">Figure </xref>2, it was possible to obtain contractile response for both Ang I and Ang II in denuded aortic rings. However, the contractile responses induced by Ang I (ME: 0.52 &#177; 0.04 g, n = 11, p &lt; 0.001) and Ang II (ME: 0.40 &#177; 0.03 g, n = 11, p &lt; 0.05) were lower in WAR (<xref ref-type="fig" rid="fig">Figure </xref>2(b)) than the response observed in the Wistar (<xref ref-type="fig" rid="fig">Figure </xref>2(a)) for Ang I (ME: 1.13 &#177; 0.08 g, n = 11) and Ang II (ME: 1.24 &#177; 0.04 g, n = 11).</p><p>It was evaluated whether this differential vascular reactivity was due to the different expression of the RAS components in the aortic tissue with intact endothelium and in endothelium-denuded aortic rings isolated from WAR and Wistar rats. As illustrated in <xref ref-type="fig" rid="fig">Figure </xref>3, the AT<sub>1</sub> receptor protein expression was increased upon endothelium removal in both WAR and Wistar. Thus, AT<sub>1</sub> expression in WAR E+ (1.21 &#177; 0.09, n = 4) and Wistar E+ (1.16 &#177; 0.05, n = 4) were lower (p &lt; 0.05) compared with WAR E– (1.60 &#177; 0.14, n = 4) and Wistar E– (1.50 &#177; 0.09, n = 4), respectively. There were no statistical differences</p><p>between WAR E– and Wistar E– or WAR E+ and Wistar E+.</p><p>According to the Western Blotting analysis, the AT<sub>2</sub> receptor expression was lower in both WAR E– (0.51 &#177; 0.06, n = 4, p &lt; 0.05) and WAR E+ (0.52 &#177; 0.07, n = 4, p &lt; 0.001) than in Wistar E– (1.30 &#177; 0.5, n = 4) and Wistar E+ (2.10 &#177; 0.4, n = 4), respectively (<xref ref-type="fig" rid="fig">Figure </xref>4). The presence or the absence of endothelium did not alter the expression of AT<sub>2</sub> receptor either WAR or Wistar rats.</p><p>As represented in <xref ref-type="fig" rid="fig">Figure </xref>5 the expression of the Mas receptor in WAR E+ (0.13 &#177; 0.02 n = 4) and WAR E– (0.16 &#177; 0.06, n = 4) was lower than its expression in Wistar E+ (0.39 &#177; 0.07, n = 4, p &lt; 0.05) and Wistar E– (0.54 &#177; 0.02, n = 4, p &lt; 0.001), respectively. The presence or the absence of endothelium did not alter the expression of Mas receptor either WAR or Wistar rats.</p><p>As shown in <xref ref-type="fig" rid="fig">Figure </xref>6, ACE expression was higher in both WAR E+ (1.41 &#177; 0.4, n = 4, p &lt; 0.001) and Wistar E+ (1.15 &#177; 0.05, n = 4, p &lt; 0.001) than in denuded aortas from WAR and Wistar, respectively. Endothelium removal decreased ACE expression in both WAR (0.28 &#177; 0.06, n = 4) and Wistar (0.11 &#177; 0.03, n = 4).</p></sec><sec id="s4"><title>4. DISCUSSION</title><p>This is the first study concerning the involvement of the RAS on the peripheral vascular activity in an animal model to study epilepsy. It was evaluated the implications of the agonist of the RAS in the contractile dysfunction on the animal model of epilepsy, the WAR strain.</p><p>It is well known that central and peripheral structures are affected by RAS activity in a way that one response influences others and vice-versa. Considering the epilepsy disorder, this relationship could contribute to the co-morbidities, including cardiovascular alterations. Although Ang II has been assumed to be the main peptide acting in the periphery, a large number of studies support the concept that it acts as a neurotransmitter or neuromodulator in specific neuronal pathways in the central nervous system [53-56]. In the present study, our experimental approach was focused on the peripheral vascular function of WAR a genetically developed strain [<xref ref-type="bibr" rid="scirp.19439-ref39">39</xref>], in animals who had not been stimulated for developing audiogenic seizures. Although it is not classified as a hypertensive status, in this study it was demonstrated that the level of systolic blood pressure of WAR was higher than that of the Wistar control group. This increased blood pressure level may be of concern because the impaired cardiovascular system is one of the possible mechanisms of cause or effect of the development of such seizures and the prevalence of sudden unexplained death in epileptic patients-SUDEP [57,58]. According to Scorza et al. [<xref ref-type="bibr" rid="scirp.19439-ref59">59</xref>], the abnormalities in cardiovascular system are involved in SUDEP. Since hypertension is an important risk factor for cardiovascular diseases, the increasing systolic blood pressure in epileptics could represent a point of the surveillance in the clinical practice. Adaptive cardiovascular reflexes could explain increased arterial pressure in WAR during seizures contributing to the cardiac manifestations that are integrated with the sympathetic and/or parasympathetic discharges triggered by seizures [<xref ref-type="bibr" rid="scirp.19439-ref60">60</xref>].</p><p>Our results show that the Ang II-induced vasoconstriction was potentiated by endothelium removal. These data are in accordance to Boulanger et al. [<xref ref-type="bibr" rid="scirp.19439-ref61">61</xref>]; Caputo et al. [<xref ref-type="bibr" rid="scirp.19439-ref62">62</xref>]; Gruetter et al. [<xref ref-type="bibr" rid="scirp.19439-ref63">63</xref>]; and Zhang et al. [<xref ref-type="bibr" rid="scirp.19439-ref64">64</xref>], who have demonstrated that this vasoconstriction is decreased by the release of endothelium-derived relaxing factors such as NO in non-epileptic vessels. In the present study, endothelium impaired the contractile response induced by both Ang I and Ang II. It has been reported that NO and Ang II have opposite effects on vascular responses as blood pressure regulators [<xref ref-type="bibr" rid="scirp.19439-ref65">65</xref>]. Since endothelium reduced the contractile response to Ang I and Ang II in aorta isolated from control (non-epileptic) rats, we suggest that an endothelium-relaxing factor could be involved in the lower response to these peptides. Otherwise, in Wistar rats relaxing endothelium-derived factors do not influence the contractile response induced by Ang II, since its response was similar in the presence and absence of endothelium. Other studies have also shown the dependence on endothelium of the contractile response induced by both Ang I and Ang II [<xref ref-type="bibr" rid="scirp.19439-ref66">66</xref>]. In addition, our results suggest that the RAS system rather than the adrenergic response is affected by endothelium in aorta from epileptic rats.</p><p>In the present study, it is interesting to note that the expression of AT<sub>1</sub> receptors in E+/E– WAR aorta was similar to their expression in E+/ E– Wistar aorta, despite the differences in the contractile responses to Ang I/Ang II observed in E– WAR and in the E+ WAR aortas. Considering the AT<sub>1</sub> receptor expression, one can suggest that it contributes to the higher contractile response in E– WAR as compared to the one detected in E+ WAR.</p><p>Due to vascular responses, AT<sub>1</sub> receptor activation and AT<sub>2</sub> receptor activation have opposite effects on blood pressure [<xref ref-type="bibr" rid="scirp.19439-ref65">65</xref>]. The activation of AT<sub>2</sub> receptors by Ang II induces endothelium-dependent vasodilation in vascular beds [<xref ref-type="bibr" rid="scirp.19439-ref66">66</xref>]. In this sense, we have evaluated the AT<sub>2</sub> receptor expression. As reported by Pueyo &amp; Michel [<xref ref-type="bibr" rid="scirp.19439-ref67">67</xref>] and Harbel et al. [<xref ref-type="bibr" rid="scirp.19439-ref68">68</xref>], the Ang II receptors are mainly of the AT<sub>1</sub> type in rat endothelial cells, but AT<sub>2</sub> receptors have also been found. Herein, AT<sub>2</sub> receptor expression in WAR aorta was not altered by the presence or absence of endothelium. AT<sub>2</sub> receptor expression was higher in the Wistar animals compared with WAR, regardless of E<sup>+</sup> or E– aortas. Otherwise, a tendency to lower AT<sub>2</sub> expression was observed for Wistar E– aorta, which could explain the lower amplitude of the contractile response induced by Ang I and Ang II.</p><p>Although AT<sub>1</sub> receptor activation and AT<sub>2</sub> receptor activation have opposite effects, it has not yet been confirmed that the AT<sub>1</sub>/AT<sub>2</sub> receptor heterodimer inhibits AT<sub>1</sub> signals [<xref ref-type="bibr" rid="scirp.19439-ref67">67</xref>]. Therefore, Mas receptor investigation could be helpful in explaining our results about the absence of the contractile response to Ang I and Ang II stimulation in the presence of endothelium since Ang (1-7) acts as an endogenous antagonist of Ang I/Ang II and blocks Ang II-mediated vasoconstriction and cell proliferation [69,70]. In our hands, Mas expression was higher in control Wistar compared with WAR aorta, in an endothelium-independent way. These results support the statement that the Mas receptor is not responsible for the differences observed in the vascular reactivity responses in WAR.</p><p>In the present investigation, ACE expression was higher in E+ WAR and E+ Wistar aorta compared with E– WAR and E– Wistar. These results suggest that a higher level of Ang I could be converted to Ang II in WAR.</p><p>The removal of the endothelium suppresses relaxing regulator factors, mainly NO. To some extent, Ang II acting on smooth muscle cells triggers a contraction that is not counterbalanced by its vasodilatory effects endothelium-dependent. It seems that in WAR animal, endothelium exerts a vasodilatory control stronger than that existing in control Wistar rats. In fact, Ang II contractile response is modified in WAR rat and the regulation by endothelium is in part involved in that alteration of Ang II response.</p></sec><sec id="s5"><title>5. CONCLUSION</title><p>The presence of endothelium impairs the contractile response induced by both peptides Ang I and Ang II in WAR aortas. It suggests that endothelial factors could have an important role in protecting the aorta vascular smooth muscle contraction stimulated by these peptides in this genetically epileptic rat strain, whose systolic blood pressure is lightly increased in na&#239;ve conditions (without developing seizures).</p></sec><sec id="s6"><title>REFERENCES</title></sec></body><back><ref-list><title>References</title><ref id="scirp.19439-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Earnest, M.P., Thomas, G.E., Eden, R.A. and Hossack, K.F. (1992) The sudden unexplained death syndrome in epilepsy: Demographic, clinical, and postmortem features. Epilepsia, 33, 310-316.  
doi:10.1111/j.1528-1157.1992.tb02321.x</mixed-citation></ref><ref id="scirp.19439-ref2"><label>2</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ficker</surname><given-names> D.M.</given-names></name>,<name name-style="western"><surname> So</surname><given-names> E.L.</given-names></name>,<name name-style="western"><surname> Shen</surname><given-names> W.K.</given-names></name>,<name name-style="western"><surname> Annegers</surname><given-names> JF</given-names></name>,<name name-style="western"><surname> O’Brien</surname><given-names> P.C.</given-names></name>,<name name-style="western"><surname> Cascino</surname><given-names> G.D. and Belau</given-names></name>,<name name-style="western"><surname> P.G. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>1998</year>)<article-title>Populationbased study of the incidence of sudden unexplained death in epilepsy</article-title><source> Neurology</source><volume> 51</volume>,<fpage> 1270</fpage>-<lpage>1274</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.19439-ref3"><label>3</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Bell</surname><given-names> G.S. and Sander</given-names></name>,<name name-style="western"><surname> J.W. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>2006</year>)<article-title>Sudden unexpected death in epilepsy. Risk factors, possible mechanisms and prevention: A reappraisal</article-title><source> Acta Neurologica Taiwanica</source><volume> 15</volume>,<fpage> 72</fpage>-<lpage>83</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.19439-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Nei, M. and Hays, R. (2010) Sudden unexpected death in epilepsy. Current Neurology and Neuroscience Reports, 10, 319-326. doi:10.1007/s11910-010-0116-4</mixed-citation></ref><ref id="scirp.19439-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Scorza, F.A., Arida, R.M., Terra, V.C. and Cavalheiro, E.A. (2010) What can be done to reduce the risk of SUDEP? Epilepsy Behavior, 18, 137-138. 
doi:10.1016/j.yebeh.2010.04.046</mixed-citation></ref><ref id="scirp.19439-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Shorvon, S. and Tomson, T. (2011) Sudden unexpected death in epilepsy. Lancet, 378, 2028-2038. 
doi:10.1016/S0140-6736(11)60176-1</mixed-citation></ref><ref id="scirp.19439-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Tchekalarova, J. and Georgiev, V. (2005) Angiotensin pep tides modulatory system: How is it implicated in the control of seizure susceptibility? Life Science, 76, 955-970.  
doi:10.1016/j.lfs.2004.10.012</mixed-citation></ref><ref id="scirp.19439-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Arga?araz, G.A., Konno, A.C., Perosa, S.R., Santiago, J.F.C., Boim, M.A., Vidotti, D.B., Varella, P.P., Costa, L.G., Canzian, M., Porcionatto, M.A., Yacubian, E.M., Sakamoto, A.C., Carrete, H. Jr., Centeno, R.S., Amado, D., Cavalheiro, E.A., Silva J.A. Jr. and Mazzacoratti, M.G. (2008) The renin-Angiotensin system is upregulated in the cortex and hippocampus of patients with temporal lobe epilepsy related to mesial temporal sclerosis. Epilepsia, 49, 1348-1357.  
doi:10.1111/j.1528-1167.2008.01581.x</mixed-citation></ref><ref id="scirp.19439-ref9"><label>9</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Peach</surname><given-names> M.J. </given-names></name>,<etal>et al</etal>. (<year>1977</year>)<article-title>Renin-Angiotensin system: Biochemistry and mechanisms of action</article-title><source> Physiological Reviews</source><volume> 57</volume>,<fpage> 313</fpage>-<lpage>370</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.19439-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Ferrario, C.M., Jessup, J., Chappell, M.C., Averill, D.B., Brosnihan, K.B., Tallant E.A., Diz, D.I., and Gallagher, P.E. (2005) Effect of Angiotensin-converting enzyme inhibition and Angiotensin II receptor blockers on cardiac Angiotensin-converting enzyme 2, Circulation, 111, 2605-2610. 
doi:10.1161/CIRCULATIONAHA.104.510461</mixed-citation></ref><ref id="scirp.19439-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Ferrario, C.M. and Strawn W.B. (2006) Role of the reninAngiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease. The American Journal of Cardiology, 98, 121-128. 
doi:10.1016/j.amjcard.2006.01.059</mixed-citation></ref><ref id="scirp.19439-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Mascareno, E., Galatioto, J., Rozenberg, I., Salciccioli, L., Kamran, H., Lazar, J.M., Liu, F., Pedrazzini, T. and Siddiqui, M.A. (2012) Cardiac lineage protein-1 (CLP-1) regulates cardiac remodeling via transcriptional modulation of diverse hypertrophic and fibrotic responses and Angiotensin II-transforming growth factor β (TGFβ1) signaling axis. Journal of Biological Chemistry, 287, 13084-13093. doi:10.1074/jbc.M111.288944</mixed-citation></ref><ref id="scirp.19439-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Matsusaka, T. and Ichikawa, I. (1997) Biological functions of Angiotensin and its receptors. Annual Review of Physiology, 59, 395-412. 
doi:10.1146/annurev.physiol.59.1.395</mixed-citation></ref><ref id="scirp.19439-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Santos, R.A.S., Campagnole-Santos, M.J. and Andrade, S. (2000) Angiotensin-(1-7): Na update. Regulatory Peptides, 91, 45-62. doi:10.1016/S0167-0115(00)00138-5</mixed-citation></ref><ref id="scirp.19439-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Vickers, C., Hales, P., Kaushik, V., Dick, L., Gavin, J., Tang, J., Godbout, K., Parsons, T., Baronas, E., Hsieh, F., Acton, S., Patane, M., Nichols, A. and Tummino, P. (2002) Hydrolysis of biological peptides by human Angiotensinconverting enzyme related carboxypeptidase. Journal of Biological Chemistry, 277, 14838-14843. 
doi:10.1074/jbc.M200581200</mixed-citation></ref><ref id="scirp.19439-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Oudit, G.Y., Crackower, M.A., Backx, P.H. and Penninger, J.M. (2003) The role of ACE2 in cardiovascular physiology. Trends in Cardiovascular Medicine, 13, 93-101. 
doi:10.1016/S1050-1738(02)00233-5</mixed-citation></ref><ref id="scirp.19439-ref17"><label>17</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Ferrario</surname><given-names> C.M.</given-names></name>,<name name-style="western"><surname> Chappell</surname><given-names> M.C.</given-names></name>,<name name-style="western"><surname> Tallant</surname><given-names> E.A.</given-names></name>,<name name-style="western"><surname> Brosnihan</surname><given-names> K.B. and Diz</given-names></name>,<name name-style="western"><surname> D.I. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>1997</year>)<article-title>Counterregulatory actions of Angiotensin-(1-7)</article-title><source> Hypertension</source><volume> 30</volume>,<fpage> 535</fpage>-<lpage>541</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.19439-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Santos, R.A., Simoes e Silva, AC.,. Maric, C., Silva, D.M., Machado, R.P., de Buhr, I., Heringer-Walther, S., Pinheiro, S.V., Lopes, M.T., Bader, M., Mendes, E.P., Lemos, V.S., Campagnole-Santos, M.J., Schultheiss H.P., Speth, R. and Walther, T. (2003) Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proceedings of the National Academy of Sciences, 100, 8258-8263. doi:10.1073/pnas.1432869100</mixed-citation></ref><ref id="scirp.19439-ref19"><label>19</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>De gasparo</surname><given-names> M.</given-names></name>,<name name-style="western"><surname> Catt</surname><given-names> C.J.</given-names></name>,<name name-style="western"><surname> Inagami</surname><given-names> Wright</given-names></name>,<name name-style="western"><surname> T.J.W. and Unger</surname><given-names> T.H. </given-names></name>,<etal>et al</etal>. (<year>2000</year>)<article-title>International union of pharmacology. XXIII. The Angiotensin II receptors</article-title><source> Pharmacological Reviews</source><volume> 52</volume>,<fpage> 415</fpage>-<lpage>472</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.19439-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Ishii, K., Takekoshi, K., Shibuya, S., Kawakami, Y., Isobe, K. and Nakai, T. (2001) Angiotensin subtype-2 receptor (AT2) negatively regulates subtype-1 receptor (AT1) in signal transduction pathways in cultured porcine adrenal medullary chromaffin cells. Journal of Hypertension, 19, 1991-1999. doi:10.1097/00004872-200111000-00009</mixed-citation></ref><ref id="scirp.19439-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Carey, R.M. (2005) Cardiovascular and renal regulation by the Angiotensin type 2 receptor: The AT2 receptor comes of age. Hypertension, 45, 840-844. 
doi:10.1161/01.HYP.0000159192.93968.8f</mixed-citation></ref><ref id="scirp.19439-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Gendron, L., Payet, M.D. and Gallo-Payet, N. (2003). The Angiotensin type 2 receptor of Angiotensin II and neuronal differentiation: from observations to mechanisms. Journal of Molecular Endocrinology, 31, 359-372. 
doi:10.1677/jme.0.0310359</mixed-citation></ref><ref id="scirp.19439-ref23"><label>23</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Horiuchi</surname><given-names> M.</given-names></name>,<name name-style="western"><surname> Akishita</surname><given-names> M. and Dzau</given-names></name>,<name name-style="western"><surname> V.J. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>1999</year>)<article-title>Recent progress in Angiotensin II type 2 receptor research in the cardiovascular system</article-title><source> Hypertension</source><volume> 33</volume>,<fpage> 613</fpage>-<lpage>621</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.19439-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Stoll, M. and Unger, T. (2001) Angiotensin and its AT2 receptor: New insights into an old system. Regulatory Peptides, 99, 175-182.  
doi:10.1016/S0167-0115(01)00246-4</mixed-citation></ref><ref id="scirp.19439-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Yan, C., Kim, D., Aizawa, T. and Berk, B.C. (2003) Functional interplay between Angiotensin II and nitric oxide: Cyclic GMP as a key mediator. Arteriosclerosis, Thrombosis, and Vascular Biology, 23, 26-36. 
doi:10.1161/01.ATV.0000046231.17365.9D</mixed-citation></ref><ref id="scirp.19439-ref26"><label>26</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Konishi</surname><given-names> M. and Su</given-names></name>,<name name-style="western"><surname> C. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>1983</year>)<article-title>Role of endothelium in dilator responses of spontaneously hypertensive rat arteries</article-title><source> Hypertension</source><volume> 5</volume>,<fpage> 881</fpage>-<lpage>886</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.19439-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Wu, C.C., Chen, S.J. and Yen, M.H. (1993) Different responses to acetylcholine in the presence of nitric oxide inhibitor in rat aortae and mesenteric arteries. Clinical and Experimental Pharmacology and Physiology, 20, 405-412.  
doi:10.1111/j.1440-1681.1993.tb01717.x</mixed-citation></ref><ref id="scirp.19439-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Osaka, T., Yamashita, H. and Koizumi, K. (1992) Inhibitory inputs to the subfornical organ from the AV3V: Involvement of GABA. Brain Research Bulletin, 29, 581-587. doi:10.1016/0361-9230(92)90126-I</mixed-citation></ref><ref id="scirp.19439-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Dampney, R.A.L., Hirooka, Y., Potts, P.D. and Head G.A. (1996) Functions of Angiotensin peptides in the rostral ventrolateral medulla. Clinical and Experimental Pharmacology and Physiology, 3, S105-S111.  
doi:10.1111/j.1440-1681.1996.tb02822.x</mixed-citation></ref><ref id="scirp.19439-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Head, G.A. (1996) Role of AT1 receptors in the central control of sympathetic vasomotor function. Clinical and Experimental Pharmacology and Physiology, 3, S93-S98. 
doi:10.1111/j.1440-1681.1996.tb02820.x</mixed-citation></ref><ref id="scirp.19439-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Muratami, H. (1996) Brain Angiotensin and circulatory control. Clinical and Experimental Pharmacology and Physiology, 23, 458-464. 
doi:10.1111/j.1440-1681.1996.tb02761.x</mixed-citation></ref><ref id="scirp.19439-ref32"><label>32</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Unger</surname><given-names> T.</given-names></name>,<name name-style="western"><surname> Becker</surname><given-names> H.</given-names></name>,<name name-style="western"><surname> Petty</surname><given-names> M.</given-names></name>,<name name-style="western"><surname> Demmert</surname><given-names> G.</given-names></name>,<name name-style="western"><surname> Schneider</surname><given-names> B.</given-names></name>,<name name-style="western"><surname> Ganten</surname><given-names> D. and Langer</given-names></name>,<name name-style="western"><surname> R.E. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>1985</year>)<article-title>Differential effects of central Angiotensin II and substance P on sympathetic nerve activity in conscious rats. Implications for cardiovascular adaptation to behavioral responses</article-title><source> Circulation Research</source><volume> 56</volume>,<fpage> 563</fpage>-<lpage>575</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.19439-ref33"><label>33</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Barnes</surname><given-names> N.M.</given-names></name>,<name name-style="western"><surname> Cheng</surname><given-names> C.H.</given-names></name>,<name name-style="western"><surname> Costall</surname><given-names> B.</given-names></name>,<name name-style="western"><surname> Naylor</surname><given-names> R.J.</given-names></name>,<name name-style="western"><surname> Williams</surname><given-names> T.J. and Wischik</given-names></name>,<name name-style="western"><surname> C.M. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>1991</year>)<article-title>Angiotensin converting enzyme density is increased in temporal cortex from patients with Alzheimer’s disease</article-title><source> European Journal of Pharmacology</source><volume> 200</volume>,<fpage> 289</fpage>-<lpage>292</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.19439-ref34"><label>34</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tian</surname><given-names> J.</given-names></name>,<name name-style="western"><surname> Shi</surname><given-names> J.</given-names></name>,<name name-style="western"><surname> Bailey</surname><given-names> K.</given-names></name>,<name name-style="western"><surname> Harris</surname><given-names> J.M.</given-names></name>,<name name-style="western"><surname> Pritchard</surname><given-names> A.</given-names></name>,<name name-style="western"><surname> Lambert</surname><given-names> J.C.</given-names></name>,<name name-style="western"><surname> Chartier-Harlin</surname><given-names> M.C.</given-names></name>,<name name-style="western"><surname> Pickering-Brown</surname><given-names> S.M.</given-names></name>,<name name-style="western"><surname> Lendon</surname><given-names> C.L. and Mann</given-names></name>,<name name-style="western"><surname> D.M. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>2004</year>)<article-title>A polymerphism in the Angiotensin 1-converting enzyme gene is associated with damage to cerebral cortical white matter in Alzheimer’s disease</article-title><source> Neuroscience Letters</source><volume> 354</volume>,<fpage> 103</fpage>-<lpage>106</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.19439-ref35"><label>35</label><mixed-citation publication-type="other" xlink:type="simple">Grammatopoulos, T.N., Ahmadi, F., Jones, S.M., Fariss, M.W., Weyhenmeyer, J.A. and Zawada, W.M. (2005) Angiotensin II protects cultured midbrain dopaminergic neurons against rotenone-induced cell death. Brain Research, 1045, 64-71. doi:10.1016/j.brainres.2005.03.038</mixed-citation></ref><ref id="scirp.19439-ref36"><label>36</label><mixed-citation publication-type="other" xlink:type="simple">Bird, E.D. (1980) Chemical pathology of Huntington’s disease. Annual Review of Pharmacology and Toxicology, 20, 533-551. doi:10.1146/annurev.pa.20.040180.002533</mixed-citation></ref><ref id="scirp.19439-ref37"><label>37</label><mixed-citation publication-type="other" xlink:type="simple">Fisher, R.S. (1989) Animal models of epilepsy. Brain Research, 14, 254-278. doi:10.1016/0165-0173(89)90003-9</mixed-citation></ref><ref id="scirp.19439-ref38"><label>38</label><mixed-citation publication-type="other" xlink:type="simple">Mishra, P.K., Kahle, E.H., Bettendorf, A.F., Dailey, J.W. and Jobe, P.C. (1993) Anticonvulsant effects of intracerebroventricularly administered norepinephrine are potentiated in the presence of monoamine oxidase inhibition in severe seizure genetically epilepsy-prone rats (GEPR9s). Life Sciences, 52, 1435-1441. 
doi:10.1016/0024-3205(93)90067-D</mixed-citation></ref><ref id="scirp.19439-ref39"><label>39</label><mixed-citation publication-type="other" xlink:type="simple">Doretto, M.C., Fonseca, C.G., L?bo, R.B., Terra, V.C., Oliveira, J.A.C. and Garcia-Cairasco, N. (2003) Quantitative study of the response to genetic selection of the Wistar Audiogenic Rat Strain (WAR). Behavior Genetics, 33, 33-41. doi:10.1023/A:1021099432759</mixed-citation></ref><ref id="scirp.19439-ref40"><label>40</label><mixed-citation publication-type="other" xlink:type="simple">Garcia-Cairasco N. (1989) Neural and ethological relations in the evaluation of motor control changes. II. Experimental models. Arquivos de Neuro-Psiquiatria, 47, 172-181.  
doi:10.1590/S0004-282X1989000200008</mixed-citation></ref><ref id="scirp.19439-ref41"><label>41</label><mixed-citation publication-type="other" xlink:type="simple">Terra, V.C. and Garcia-Cairasco, N. (1992) Neuroethological evaluation of audiogenic seizures and audiogeniclike seizures induced by microinjection of bicuculline into the inferior colliculus. II. Effects of nigral clobazam microinjections. Behavioural Brain Research, 52, 19-28.  
doi:10.1016/S0166-4328(05)80321-3</mixed-citation></ref><ref id="scirp.19439-ref42"><label>42</label><mixed-citation publication-type="other" xlink:type="simple">Terra, V.C. and Garcia-Cairasco, N. (1994) NMDA-dependent audiogenic seizures are differentially regulated by inferior colliculus subnuclei. Behavioural Brain Research, 62, 29-39. doi:10.1016/0166-4328(94)90035-3</mixed-citation></ref><ref id="scirp.19439-ref43"><label>43</label><mixed-citation publication-type="other" xlink:type="simple">Tsutsui, J., Terra, V.C., Oliveira, J.A. and Garcia-Cairasco, N. (1992) Neuroethological evaluation of audiogenic seizures and audiogenic-like seizures induced by microinjection of bicuculline into the inferior colliculus. I. Effects of midcollicular knife cuts. Behavioural Brain Research, 52, 7-17. doi:10.1016/S0166-4328(05)80320-1</mixed-citation></ref><ref id="scirp.19439-ref44"><label>44</label><mixed-citation publication-type="other" xlink:type="simple">Garcia-Cairasco, N., Terra, V.C. and Doretto, M.C. (1993) Midbrain substrates of audiogenic seizures in rats. Behavioural Brain Research, 58, 57-67.  
doi:10.1016/0166-4328(93)90090-D</mixed-citation></ref><ref id="scirp.19439-ref45"><label>45</label><mixed-citation publication-type="other" xlink:type="simple">Garcia-Cairasco, N., Wakamatsu, H., Oliveira, J.A., Gomes, E.L., Del Bel, E.A. and Mello LE. (1996) Neuroethological and morphological (Neo-Timm staining) correlates of limbic recruitment during the development of audiogenic kindling in seizure susceptible Wistar rats. Epilepsy Research, 26, 177-192.  
doi:10.1016/S0920-1211(96)00050-2</mixed-citation></ref><ref id="scirp.19439-ref46"><label>46</label><mixed-citation publication-type="other" xlink:type="simple">Moraes, M.F., Del Vecchio, F., Terra, V.C. and GarciaCairasco, N. (2000) Time evolution of acoustic information processing in the mesencephalon of Wistar rats. Neuroscience Letters, 284, 13-16. 
doi:10.1016/S0304-3940(00)00978-2</mixed-citation></ref><ref id="scirp.19439-ref47"><label>47</label><mixed-citation publication-type="other" xlink:type="simple">Romcy-Pereira, R.N. and Garcia-Cairasco, N. (2003) Hippocampal cell proliferation and epileptogenesis after audiogenic kindling are not accompanied by mossy fiber sprouting or Fluoro-Jade staining. Neuroscience, 119, 533-546. doi:10.1016/S0306-4522(03)00191-X</mixed-citation></ref><ref id="scirp.19439-ref48"><label>48</label><mixed-citation publication-type="other" xlink:type="simple">Galvis-Alonso, O.Y., Cortes De Oliveira, J.A. and GarciaCairasco, N. (2004) Limbic epileptogenicity, cell loss and axonal reorganization induced by audiogenic and amygdala kindling in wistar audiogenic rats (WAR strain). Neuroscience, 125, 787-802. 
doi:10.1016/j.neuroscience.2004.01.042</mixed-citation></ref><ref id="scirp.19439-ref49"><label>49</label><mixed-citation publication-type="other" xlink:type="simple">Doretto, M.C., Garcia-Cairasco, N., Pimenta, N.J., Souza, D.A. and Tatsuo MA. (1998) Dipyrone, a novel anticonvulsant agent? Insights from three experimental epilepsy models. NeuroReport, 9, 2415-2421. 
doi:10.1097/00001756-199807130-00048</mixed-citation></ref><ref id="scirp.19439-ref50"><label>50</label><mixed-citation publication-type="other" xlink:type="simple">Ribeiro, A.M., dos Santos, W.F. and Garcia-Cairasco, N. (2000) Neuroethological analysis of the effects of spider venom from Scaptocosa raptoria (Lycosidae: Araneae) microinjected in the lateral ventricle of Wistar rats. Brain Research Bulletin, 52, 581-588. 
doi:10.1016/S0361-9230(00)00300-2</mixed-citation></ref><ref id="scirp.19439-ref51"><label>51</label><mixed-citation publication-type="other" xlink:type="simple">Rossetti, F., Rodrigues, M.C., de Oliveira, J.A. and Garcia-Cairasco, N. (2006) EEG wavelet analyses of the striatum-substantia nigra pars reticulata-superior colliculus circuitry: audiogenic seizures and anticonvulsant drug administration in Wistar audiogenic rats (War strain). Epilepsy Research, 72, 192-208. 
doi:10.1016/j.eplepsyres.2006.08.001</mixed-citation></ref><ref id="scirp.19439-ref52"><label>52</label><mixed-citation publication-type="other" xlink:type="simple">Pereira, M.G., Gitaí, D.L., Pa?ó-Larson, M.L., Pesquero, J.B., Garcia-Cairasco, N. and Costa-Neto CM. (2008) Modulation of B1 and B2 kinin receptors expression levels in the hippocampus of rats after audiogenic kindling and with limbic recruitment, a model of temporal lobe epilepsy. International Immunopharmacology, 8, 200-205.  
doi:10.1016/j.intimp.2007.07.028</mixed-citation></ref><ref id="scirp.19439-ref53"><label>53</label><mixed-citation publication-type="other" xlink:type="simple">Allen, A.M., Zhuo, J., Mendelsohn, F.A. (2001) AT1-receptors in the central nervous system. Journal of the ReninAngiotensin-Aldosterone System, 2, S95-S101. 
doi:10.1177/14703203010020011701</mixed-citation></ref><ref id="scirp.19439-ref54"><label>54</label><mixed-citation publication-type="other" xlink:type="simple">Wright, J.W. and Harding, J. (2004) The brain Angiotensin system and extracellular matrix molecules in neural plasticity, learning and memory. Progress in Neurobiology, 72, 263-293. doi:10.1016/j.pneurobio.2004.03.003</mixed-citation></ref><ref id="scirp.19439-ref55"><label>55</label><mixed-citation publication-type="other" xlink:type="simple">Wright, J.W., Reichert, J.R., Davis, C.J. and Harding, J.W. (2002) Neuronal plasticity and the brain renin-Angiotensin system. Neuroscience &amp; Biobehavioral Reviews, 26, 529-552. doi:10.1016/S0149-7634(02)00019-2</mixed-citation></ref><ref id="scirp.19439-ref56"><label>56</label><mixed-citation publication-type="other" xlink:type="simple">Pan, H.L. (2004) Brain Angiotensin II and synaptic transmission. The Neuroscientist, 10, 422-431. 
doi:10.1177/1073858404264678</mixed-citation></ref><ref id="scirp.19439-ref57"><label>57</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sundt</surname><given-names> T.M.</given-names></name>,<name name-style="western"><surname> Sharborough</surname><given-names> F.W.</given-names></name>,<name name-style="western"><surname> Piegras</surname><given-names> D.G.</given-names></name>,<name name-style="western"><surname> Kearns</surname><given-names> T.P.</given-names></name>,<name name-style="western"><surname> Messick</surname><given-names> J.M. and O’Fallon</given-names></name>,<name name-style="western"><surname> W.M. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>1981</year>)<article-title>Correlation of cerebral flow and electroencephalographic changes during carotid endarterectomy</article-title><source> Mayo Clinic Proceedings</source><volume> 56</volume>,<fpage> 533</fpage>-<lpage>543</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.19439-ref58"><label>58</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Lhatoo</surname><given-names> S.D.</given-names></name>,<name name-style="western"><surname> Langan</surname><given-names> Y. and Sander</given-names></name>,<name name-style="western"><surname> J.W. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>1999</year>)<article-title>Sudden unexpected death in epilepsy</article-title><source> Postgraduate Medical Journal</source><volume> 75</volume>,<fpage> 706</fpage>-<lpage>709</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.19439-ref59"><label>59</label><mixed-citation publication-type="other" xlink:type="simple">Scorza, F.A., Arida, R.M., Cavalheiro, E.A. and Silva, M.R. (2012) Because scientists are unable to explain the unexplained, screening for cardiovascular abnormalities is a good method to protect against sudden unexpected death in patients with epilepsy. Clinics (Sao Paulo), 67, 1-2. doi:10.6061/clinics/2012(01)01</mixed-citation></ref><ref id="scirp.19439-ref60"><label>60</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Sevcencu</surname><given-names> C. and Struijk</given-names></name>,<name name-style="western"><surname> J.J. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>2010</year>)<article-title>Autonomic alterations and cardiac changes in epilepsy</article-title><source> Epilepsia</source><volume> 51</volume>,<fpage> 725</fpage>-<lpage>737</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.19439-ref61"><label>61</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Boulanger</surname><given-names> C.M.</given-names></name>,<name name-style="western"><surname> Caputo</surname><given-names> L. and Levy B.I. </given-names></name>,<etal>et al</etal>. (<year>1995</year>)<article-title>Endothelial AT,-mediated release of nitric oxide decreases angiotensin contraction in rat carotid artery</article-title><source> Hypertension</source><volume> 26</volume>,<fpage> 752</fpage>-<lpage>757</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.19439-ref62"><label>62</label><mixed-citation publication-type="other" xlink:type="simple">Caputo, L., Benessiano, J., Boulanger, C.M. and Levy, B. (1995) Angiotensin II increases cyclic guanosine monophosphate content via endothelia Angiotensin II AT~subtype receptors in the rat carotid artery. Arteriosclerosis, Thrombosis, and Vascular Biology, 15, 1646-1651. 
doi:10.1161/01.ATV.15.10.1646</mixed-citation></ref><ref id="scirp.19439-ref63"><label>63</label><mixed-citation publication-type="other" xlink:type="simple">Gruetter, C.A., Ryan, C.A., Lemke, S.M., Bailly, D.A., Fox, M.K. and Schoepp, D.D. (1988) Endothelium-dependent modulation of Angiotensina lI-induced contraction in blood vessels. European Journal of Pharmacology, 146, 85-95. doi:10.1016/0014-2999(88)90489-X</mixed-citation></ref><ref id="scirp.19439-ref64"><label>64</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, J., Van Meel, C.A., Pfaffendorf, M., Zhang, J. and Van Zwiten, P.A. (1994) Endothelium-dependent, nitric oxide-mediated inhibition of Angiotensina II-induced contraction in rabbit aorta. European Journal of Pharmacology, 262, 247-253.  
doi:10.1016/0014-2999(94)90738-2</mixed-citation></ref><ref id="scirp.19439-ref65"><label>65</label><mixed-citation publication-type="other" xlink:type="simple">Harada, S., Nakata, T., Oguni, A., Kido, H., Hatta, T., Fukuyama, R., Fushiki, S., Sasaki, S. and Takeda, K. (2002) Contrasting Effects of Angiotensin Type 1 and 2 Receptors on Nitric Oxide Release under Pressure. Hypertension Research, 25, 779-786. doi:10.1291/hypres.25.779</mixed-citation></ref><ref id="scirp.19439-ref66"><label>66</label><mixed-citation publication-type="other" xlink:type="simple">Lemos, V.S., C?rtes, S.F., Silva, D.M.R., CampagnoleSantos, M.J. and Santos, R.A.S. (2002) Angiotensin-(1-7) is involved in the endothelium-dependent modulation of phenylephrine-induced contraction in the aorta of mRen-2 transgenic rats, British Journal of Pharmacology, 135, 1743-1748. doi:10.1038/sj.bjp.0704630</mixed-citation></ref><ref id="scirp.19439-ref67"><label>67</label><mixed-citation publication-type="other" xlink:type="simple">Pueyo, M.E. and Michel, J.B. (1997) Angiotensin II receptors in endothelial cells. General Pharmacology, 29, 691-696. doi:10.1016/S0306-3623(97)00021-9</mixed-citation></ref><ref id="scirp.19439-ref68"><label>68</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Haberl</surname><given-names> R.</given-names></name>,<name name-style="western"><surname> Anneser</surname><given-names> F.</given-names></name>,<name name-style="western"><surname> Villringer</surname><given-names> A. and Einhiupl</given-names></name>,<name name-style="western"><surname> K.M. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>1990</year>)<article-title>Angiotensin induces endothelium-dependent vasodilatation of rat cerebral arterioles</article-title><source> American Journal of Physiology</source><volume> 258</volume>,<fpage> 1840</fpage>-<lpage>1846</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.19439-ref69"><label>69</label><mixed-citation publication-type="other" xlink:type="simple">Abdalla, S., Lother, H., Abdel-Tawab, A.M. and Quitterer, U. (2001) The Angiotensina II AT2 receptor is an AT1 receptor antagonist. The Journal of Biological Chemistry, 276, 39721-29726. doi:10.1074/jbc.M105253200</mixed-citation></ref><ref id="scirp.19439-ref70"><label>70</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Tallant</surname><given-names> E.A.</given-names></name>,<name name-style="western"><surname> Diz</surname><given-names> D.I. and Ferrario</given-names></name>,<name name-style="western"><surname> C.M. </surname><given-names>  </given-names></name>,<etal>et al</etal>. (<year>1999</year>)<article-title>Stateof-the-Art lecture. Antiproliferative actions of Ang Iotensin-(1-7) in vascular smooth muscle</article-title><source> Hypertension</source><volume> 34</volume>,<fpage> 950</fpage>-<lpage>957</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref></ref-list></back></article>